Oppenheimer analyst Jay Olson maintained a Hold rating on Enanta Pharmaceuticals (NASDAQ:ENTA) on Monday, setting a price target of $55, which is approximately 3.60% above the present share price of $53.09.
Olson expects Enanta Pharmaceuticals to post earnings per share (EPS) of -$1.46 for the first quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Hold rating of shares in Enanta Pharmaceuticals, with an average price target of $54.8.
The analysts price targets range from a high of $87 to a low of $30.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $23.63 million and a net profit of -$19.78 million. The company's market cap is $1.07 billion.
According to TipRanks.com, Oppenheimer analyst Jay Olson is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 7.4% and a 51.64% success rate.
Enanta Pharmaceuticals, Inc. operates as a biotechnology company. It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. The firm offers the medicine under the brands Mavyret and Viekira Pak. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.